CJC-1295

CJC-1295 is a synthetic, long-acting analogue of GHRH that incorporates a Drug Affinity Complex (DAC) which covalently binds to endogenous albumin, significantly prolonging its half-life to approximately 6-8 days. This binding mechanism allows for a sustained, moderate increase in baseline growth hormone levels, as opposed to the sharp pulses seen with Sermorelin. It effectively stimulates GH release by binding to the GHRH-R, leading to increased IGF-1 production. Research focuses on its unique pharmacokinetic profile for treating GH deficiency, improving body composition (reducing fat mass while preserving lean mass), and enhancing sleep quality in elderly populations. Unlike other GHRH analogues, CJC-1295 demonstrates a reduced potential for pituitary desensitization. Researchers must account for its extended half-life when designing washout periods in long-term endocrine studies.